- Conditions
- Asthma, Rhinitis, Sinusitis
- Interventions
- Mometasone Furoate monohydrate, Placebo
- Drug · Other
- Lead sponsor
- JHSPH Center for Clinical Trials
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 388 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 19
- States / cities
- Tucson, Arizona • San Diego, California • Denver, Colorado + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1369–1392
of 17,848
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Schizophrenia
- Interventions
- SEP-363856, Placebo
- Drug · Other
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 538 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 35
- States / cities
- Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 26 more
- Conditions
- Obsessive-Compulsive Disorder
- Interventions
- Tolcapone 200 MG
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Pulmonary Hypertension of Newborn
- Interventions
- INOmax
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 27 Weeks to 40 Weeks
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 27 more
- Conditions
- Gram-Positive Infections
- Interventions
- IV Tedizolid Phosphate, Oral Suspension Tedizolid Phosphate
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 1 Day to 24 Months
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 7
- States / cities
- Little Rock, Arkansas • Orange, California • San Diego, California + 4 more
- Conditions
- Asthma
- Interventions
- TEV-56248, Albuterol sulfate
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 2,769 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 157
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Paradise Valley, Arizona + 113 more
- Conditions
- Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation
- Interventions
- Vorasidenib
- Drug
- Lead sponsor
- Institut de Recherches Internationales Servier (I.R.I.S.)
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 6
- States / cities
- Los Angeles, California • San Francisco, California • Chicago, Illinois + 3 more
- Conditions
- Eosinophilic Asthma
- Interventions
- Reslizumab, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Jasper, Alabama + 58 more
- Conditions
- Dementia
- Interventions
- SPIRIT-in person, SPIRIT-remote, Usual care
- Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Evanston, Illinois
- Conditions
- Herpes Simplex, HIV Infections
- Interventions
- Foscarnet sodium
- Drug
- Lead sponsor
- Astra USA
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 5 more
- Conditions
- Hyperplasia, Chronic Renal Failure
- Interventions
- edifoligide (E2F Decoy)
- Drug
- Lead sponsor
- Anesiva, Inc.
- Industry
- Eligibility
- 18 Years to 79 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 21
- States / cities
- Los Angeles, California • Hudson, Florida • Miami, Florida + 15 more
- Conditions
- Psoriasis
- Interventions
- Ustekinumab, Guselkumab, Placebo for ustekinumab, Placebo for guselkumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 872 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 26 more
- Conditions
- Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
- Interventions
- Atezolizumab, Cabozantinib, Lenvatinib
- Biological · Drug
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 16
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Weston, Florida + 11 more
- Conditions
- Arthritis Shoulder
- Interventions
- Glenohumeral Injection
- Procedure
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Prolonged Air Leak
- Interventions
- Treatment with HUD IBV Valve System
- Device
- Lead sponsor
- Olympus Corporation of the Americas
- Industry
- Eligibility
- Not listed
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 13
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Springfield, Illinois + 9 more
- Conditions
- Metastatic Endometrial Cancer
- Interventions
- Avelumab, Talazoparib, Axitinib
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Boston, Massachusetts
- Conditions
- Chronic Myeloid Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-positive
- Interventions
- Dasatinib
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Anaheim, California • Los Angeles, California + 15 more
- Conditions
- Stress, Psychological, Mental Health Wellness
- Interventions
- Familias Inmigrantes Empoderándose contra eStrés Tomando Acción (FIESTA)
- Behavioral
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 14 Years to 17 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- CliniMacs TCR alpha-beta-Biotin system
- Device
- Lead sponsor
- Michael Pulsipher
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Oakland, California • Palo Alto, California + 8 more
- Conditions
- Moderate to High-risk Noncardiac Surgery
- Interventions
- AcumenTM HPI Software Feature, Non-protocolized Standard of Care
- Device · Other
- Lead sponsor
- Edwards Lifesciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 407 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 11
- States / cities
- Sacramento, California • Chicago, Illinois • Boston, Massachusetts + 8 more
- Conditions
- Dyslipidemia
- Interventions
- Niacin extended-release (NER), Niacin extended-release (NER) placebo, Aspirin (ASA), Aspirin (ASA) placebo
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Anaheim, California • Walnut Creek, California + 35 more
- Conditions
- Contraception
- Interventions
- Levonorgestrel (BAY98-7196)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 1,471 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 79
- States / cities
- Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 67 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV LID cp ΔM2-2 Vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 2 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Delandistrogene Moxeparvovec, Standard of Care
- Genetic · Drug
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years and older · Male only
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2038
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 26 more